Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Xeris Biopharma Holdings, Inc. keeps $11 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Xeris Biopharma’s revenue beat expectations as sales climbed sharply year over year, based on preliminary results for the third fiscal quarter of 2026 reported on November 5, 2026. Revenue rose 44% to about $107.2 million (up from about $74.4 million a year ago) and topped consensus, with revenue of $107.2 million versus the $101.7 million estimate (+5.4%). Profitability was supported by high product-level margins, with gross margin at roughly 88% and operating margin near 16%, alongside operating income of about $16.9 million on gross profit of roughly $94.8 million. Cash generation also stood out, with operating cash flow of about $35.5 million, and the company repurchased about $0.8 million of stock during the period. For the next period, consensus calls for EPS of $0.03 on revenue of $111.0 million.
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. develops and commercializes specialty therapies in biotechnology, centered on endocrinology, neurology, and gastroenterology, and generated $291.8 million of revenue in FY2025. The NASDAQ-listed company, traded as XERS, builds its portfolio around proprietary formulation technologies and a focused set of marketed products.
Today's Snapshot
XERS closed 1.1% above yesterday's close, outperforming a weaker sector. Trading was lighter than usual, with volume about half of its usual level. Xeris Biopharma raised its revenue forecast.
Trading Volume
Below 10d avg (4.7M)
2.7M
vs S&P 500 Today
Outperforming Market
+1.39%
Updated: November 18, 2026 at 21:10 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$8.73 - $15.66Buy
- RSI (14)86.29Sell
- Stochastic %K (14, 3, 3)96.44Sell
- MACD Level (12, 26)1.87Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.